$15.27
0.07% today
Nasdaq, Feb 28, 05:18 pm CET
ISIN
US87164F1057
Symbol
SNDX
Sector
Industry

Syndax Pharmaceuticals Inc Stock price

$15.28
+1.00 7.00% 1M
-5.53 26.57% 6M
+2.06 15.58% YTD
-9.13 37.40% 1Y
-0.31 1.99% 3Y
+4.53 42.14% 5Y
+3.27 27.23% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.29 1.86%
ISIN
US87164F1057
Symbol
SNDX
Sector
Industry

Key metrics

Market capitalization $1.30b
Enterprise Value $915.51m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 57.22
P/S ratio (TTM) P/S ratio 81.52
P/B ratio (TTM) P/B ratio 3.57
Revenue (TTM) Revenue $16.00m
EBIT (operating result TTM) EBIT $-321.21m
Free Cash Flow (TTM) Free Cash Flow $-258.86m
Cash position $389.61m
EPS (TTM) EPS $-3.63
P/E forward negative
P/S forward 27.02
EV/Sales forward 18.97
Short interest 26.23%
Show more

Is Syndax Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Syndax Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Syndax Pharmaceuticals Inc forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a Syndax Pharmaceuticals Inc forecast:

Buy
93%
Hold
7%

Financial data from Syndax Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
16 16
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 106 106
96% 96%
662%
- Research and Development Expense 231 231
66% 66%
1,445%
-321 -321
66% 66%
-2,008%
- Depreciation and Amortization 0.01 0.01
97% 97%
0%
EBIT (Operating Income) EBIT -321 -321
66% 66%
-2,008%
Net Profit -297 -297
69% 69%
-1,857%

In millions USD.

Don't miss a Thing! We will send you all news about Syndax Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Syndax Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
3 days ago
WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:
Neutral
GlobeNewsWire
4 days ago
WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its fourth quarter and full year 2024 financial results and provide a business update on Monday, March 3, 2025.
Neutral
GlobeNewsWire
18 days ago
NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
More Syndax Pharmaceuticals Inc News

Company Profile

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include candidate and entinostat. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.

Head office United States
CEO Michael Metzger
Employees 184
Founded 2005
Website www.syndax.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today